从2017年美国临床肿瘤学会大会报告看早期乳腺癌治疗加减法

doi:10.6040/j.issn.1671-7554.0.2017.897

摘要/Abstract

摘要： 乳腺癌的治疗正朝着精准医疗的方向迈进。2017年美国临床肿瘤学会大会报告围绕着乳腺癌治疗的加减法进行了充分的讨论,就早期乳腺癌的治疗,从传统的手术治疗、化疗、内分泌治疗,到靶向治疗和新治疗靶点的发现,均有新的临床试验结果更新,为给不同患者制定有效、损伤小且经济的治疗方案提供了新的依据。

关键词: 早期乳腺癌, 美国临床肿瘤学会, 治疗进展, 化疗, 内分泌治疗, 靶向治疗

Abstract: The treatment of breast cancer is moving forward to precision medicine. American Society of Clinical Oncology Meeting went deep into a full discussion on the addition and subtraction of breast cancer treatment in 2017. The results of many clinical trials were updated in the treatment of early breast cancer, from the traditional surgery, chemo- 山东大学学报 (医学版)56卷1期 -王殊,等.从2017年美国临床肿瘤学会大会报告看早期乳腺癌治疗加减法 \=-therapy and endocrine therapy, to anti-HER2 therapy and the finding of new therapeutic targets. The meeting gave us a new sight on finding the effective, less injured and economic treatment for the patients with early breast cancer.

Key words: Early breast cancer, American Society of Clinical Oncology, Treatment progress, Chemotherapy, Endocrine therapy, Targeted therapy

中图分类号:

R711

王殊,彭媛. 从2017年美国临床肿瘤学会大会报告看早期乳腺癌治疗加减法[J]. 山东大学学报 (医学版), 2018, 56(1): 17-21.

WANG Shu, PENG Yuan. Treatment of early breast cancer: more or less? Study from the 2017 American Society of Clinical Oncology Annual Meeting[J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 17-21.

参考文献

[1] Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med, 2002, 347(16): 1233-1241.
[2] Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncol, 2010,11(10): 927-933.
[3] 刘淼,王殊,彭媛,等. ACOSOG Z0011试验标准用于中国前哨淋巴结阳性乳腺癌患者以避免腋窝淋巴结清扫的可行性研究[J]. 中国癌症杂志,2015,25(2): 135-140. LIU Miao, WANG Shu, PENG Yuan, et al. The exportability of the criteria defined by Z0011 trial for selecting patients who are eligible for omitting ALND after a positive SLNB result in China[J]. China Oncology, 2015, 25(2): 135-140.
[4] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. breast cancer, version 3.2017[EB/OL].[2017-11-10]. http//www.nccn.org/professionals/physician.gls/pdf/breast.pdf.
[5] Morrow M, Abrahamse P, Hofer TP, et al. Trends in reoperation after initial lumpectomy for breast cancer addressing overtreatment in surgical management[J]. JAMA Oncol, Published online, June 5, 2017. doi:10.1001/jamaoncol.2017.0774.
[6] Gluz O, Nitz UA, Christgen M, et al. West German study group phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment[J]. J Clin Oncol, 2016, 34(20): 2341-2349.
[7] Harbeck N, Gluz O, Clemens M, et al. Prospective WSG phase III Plan B trial: final analysis on adjuvant 4EC→4Doc vs. 6Docetaxel/Cyclophosphamidein high clinical and intermediate/high genomic risk HER2-negative early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.504.
[8] Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49(NRG Oncology)[J]. J Clin Oncol, 2017, 35(23): 2647-2655.
[9] van Ramshorst MS, van Werkhoven E, Honkoop AH, et al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: the TRAIN-2 study[J]. Breast, 2016, 29: 153-159. doi: 10.1016/j.breast.2016.07.017.
[10] Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816.
[11] Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med, 2016, 375(3): 209-219.
[12] Colleoni M, Luo W, Karlsson P, et al. A phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.503.
[13] Sabnis GJ, Macedo LF, Goloubeva O, et al. Stopping treatment can reverse acquired resistance to letrozole[J]. Cancer Res, 2008, 68(12): 4518-4524.
[14] Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer(NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800.
[15] de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response[J]. Lancet Oncol, 2014, 15(10): 1137-1146.
[16] von Minckwitz G, Procter M, de Azambuja E, et al. A randomized comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.18_suppl.LBA500.
[17] von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131.
[18] Moreno-Aspitia A, Holmes E, Jackisch C, et al. Updated results from the phase III ALTTO trial(BIG 2-06; NCCTG/Alliance N063D)comparing one year of anti-HER2 therapy with lapatinib alone(L), trastuzumab alone(T), their sequence(T→L)or their combination(L+T)in the adjuvant treatment of HER2-positive early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.502.
[19] Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant(HERA)trial[J]. Lancet, 2017, 389(10075): 1195-1205.
[20] Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer(PHARE): a randomized phase 3 trial[J]. Lancet Oncol, 2013, 14(8): 741-748.
[21] Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial[J]. J Clin Oncol, 2009, 27(34): 5685-5692.
[22] Conte PF, Bisagni G, Frassoldati A, et al. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: results of the phase III multicentric Italian Short-HER study[EB/OL].(2017-08-20).[2017-09-19].http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.501.
[23] Bartsch R, de Azambuja E. I-SPY 2: optimising cancer drug development in the 21st century[J]. ESMO Open, 2016, 1(5): e000113. doi:10.1136/esmoopen-2016-000113.
[24] Severson TM, Wolf DM, Yau C, et al. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting[J]. Breast Cancer Res, 2017, 19(1): 99. doi: 10.1186/s13058-017-0861-2.
[25] Echavarria I, López-Tarruella S, Márquez-Rodas I. Neratinib for the treatment of HER2-positive early stage breast cancer[J]. Expert Rev Anticancer Ther, 2017, 17(8): 669-679.
[26] Nanda R, Liu MC, Yee D, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer: result from the I-SPY 2 trial[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.508.

相关文章 15

[1]	阮祥燕,程姣姣,杜娟,谷牧青. 卵巢组织冷冻保存[J]. 山东大学学报 (医学版), 2022, 60(9): 24-30.
[2]	秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[3]	王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117.
[4]	哈春芳,李茹月. 卵巢癌耐药机制与靶向治疗策略的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 117-123.
[5]	初竹秀,赵文静,李小燕,孔晓丽,马婷婷,江立玉,杨其峰. 218例女性乳腺癌患者行新辅助化疗及伴随分子标志物改变的临床价值[J]. 山东大学学报 (医学版), 2021, 59(9): 130-139.
[6]	焉传祝,王伟,纪坤乾,赵玉英. 线粒体与脑疾病[J]. 山东大学学报 (医学版), 2020, 1(8): 34-41.
[7]	陈安静,张训. 靶向小类泛素化修饰的胶质瘤治疗新策略[J]. 山东大学学报 (医学版), 2020, 1(8): 88-94.
[8]	张喜琴,祝守慧,刘宁,王玉,陈家帧,胡旭东. PEG-rhG-CSF对80例小细胞肺癌同步放化疗预防中性粒细胞减少的临床观察[J]. 山东大学学报 (医学版), 2020, 58(12): 43-46.
[9]	陈波,张磊. 2017年乳腺癌新辅助治疗进展[J]. 山东大学学报 (医学版), 2018, 56(1): 12-16.
[10]	刘荫华,赵婧祎,辛灵. 美国临床肿瘤学会多基因检测临床实践指南更新及临床意义[J]. 山东大学学报 (医学版), 2018, 56(1): 1-5.
[11]	石爱平,徐格格,解新鹏. St.Gallen会议乳腺癌新辅助治疗回顾[J]. 山东大学学报 (医学版), 2018, 56(1): 6-11.
[12]	董伟,邢乃栋,吕家驹,刘帅,孙亮,曹庆伟,董宇昊,刘钊,丁森泰. 靶向抑制有丝分裂驱动蛋白治疗多西紫杉醇耐药前列腺癌的体外疗效[J]. 山东大学学报（医学版）, 2017, 55(9): 23-30.
[13]	赵作辉,李翠玲,王道光,王风芹,曲宏懿,丁森泰,巩晶,吕家驹,杨静华. MnSOD乙酰化对肾透明细胞癌786-O细胞增殖、凋亡的影响[J]. 山东大学学报（医学版）, 2017, 55(9): 31-35.
[14]	殷雷,殷睿,李文佳,刘帅,吕家驹. CYLD抑制自噬提高膀胱癌细胞吉西他滨化疗敏感性[J]. 山东大学学报（医学版）, 2017, 55(8): 1-6.
[15]	董秀红. 认知催眠疗法减轻胃癌化疗患者癌因性疲乏的疗效观察[J]. 山东大学学报（医学版）, 2016, 54(7): 56-59.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed